Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Accumulated Expenses (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Accumulated Expenses for 8 consecutive years, with $855132.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 74.78% to $855132.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $855132.0 through Dec 2025, down 74.78% year-over-year, with the annual reading at $1.6 million for FY2025, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2025 was $855132.0 at Outlook Therapeutics, down from $1.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $5.3 million in Q2 2025, with the low at $565909.0 in Q1 2025.